This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts

EYLEA® (aflibercept) 8 mg

Innovative Mechanism of Action

Mechanism of Action

EYLEA 8mg provides 4x the molar dose of aflibercept compared with EYLEA 2mg, resulting in an effective concentration for longer in the eye*

 

What is a Higher Molar Dose?

Theoretically, a higher Molar dose is able to suppress disease activity longer than Eylea 2mg thereby resulting in sustained disease control, in the eye.*

Mechanism of Action

1:1 BINDING

Aflibercept traps VEGF and PIGF ligand dimers, forming inert 1:1 complexes

LONG-LASTING ANTI-VEGF ACTIVITY

PK models estimate that aflibercept 8 mg exhibits an unexpected 34% slower ocular clearance than aflibercept 2 mg; slower ocular clearance facilitates longer VEGF suppression

*Based on mathematical modelling and the clinical relevance is unknown

Prescribing information for EYLEA® (aflibercept) can be found here:

EYLEA® Prescribing Information
Dosing

Discover proactive dosing in nAMD and DME

Safety

Explore the safety profile of EYLEA 8mg

Abbreviations

DME
, diabetic macular oedema;
Fc
, fragment crystallisable;
IgG
, immunoglobulin G;
nAMD
, neovascular (wet) age-related macular degeneration;
PK
, pharmacokinetic;
PIGF
, placental growth factor;
VEGF
, vascular endothelial growth factor;
VEGFR
, vascular endothelial growth factor receptor.

PP-EYL_8mg-IE-0158-1   |   January 2026

    Referencesexpand_less
    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.
    • 2
      Veritti D, et al. Pharmaceutics 2023;15:1416.
    • 3
      Papadopoulos N, et al. Angiogenesis 2012;15:171–185
    • 4
      Kanda A, et al. Sci Rep 2015;5:17946.
    • 5
      Amadio M, et al. Pharmacol Res 2016;103:253–269.
    • 6
      Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.
    • 7
      EMA. EYLEA EPAR assessment report 2014. Available at: https://www.ema.europa.eu/en/documents/variation-report/eylea-h-c-2392-ii-0013-epar-assessment-report-variation_en.pdf. Accessed: December 2025.
    • 8
      Holash J, et al. Proc Natl Acad Sci USA 2002;9:11393–11398.
    • 9
      EYLEA (aflibercept) – European public assessment report. Available at: https://www.ema.europa.eu/en/documents/overview/eylea-epar-medicine-overview_en.pdf. Accessed: December 2025.